title: Imidafenacin on bladder and cognitive function in neurologic OAB patients.
abstract: OBJECTIVE
  To explore imidafenacin's effects on bladder and cognitive function in neurologic overactive bladder (OAB) patients.
  
  
  METHODS
  Sixty-two subjects (25 men, 37 women; mean age 70 years (25-86) with OAB due to neurologic diseases) were enrolled in the study. We conducted a urinary symptom survey and cognitive tests (MMSE, FAB, ADAS-cog) in all patients. We performed urodynamics in 35 patients and measured real-time near-infrared spectroscopy (NIRS)-urodynamics in eight patients before and after the administration of imidafenacin, an anticholinergic agent, for 3 months at 0.2 mg/day.
  
  
  RESULTS
  Imidafenacin significantly ameliorated urinary urgency, nighttime urinary frequency, and quality of life index (p < 0.05). Three cognitive measures did not change significantly. Urodynamics showed increased bladder capacity (p < 0.05) but detrusor overactivity did not change significantly. NIRS showed that the subtraction of oxyhemoglobin between the start of filling and the first sensation increased in the bilateral prefrontal area but without statistical significance.
  
  
  CONCLUSIONS
  Imidafenacin ameliorated bladder sensation without cognitive worsening, with a trend of prefrontal activation. Regarding cognitive function, imidafenacin is safely used in OAB patients due to neurologic diseases.
  
  
  CONCLUSIONS
  In order to explore imidafenacin (anticholinergic agent)'s effects on bladder and brain function, we performed urinary questionnaire, cognitive tests, urodynamics and near-infrared spectroscopy (selected cases) in 62 overactive bladder (OAB) patients due to various neurologic diseases. As a result, imidafenacin ameliorated bladder sensation without cognitive worsening, with a trend of prefrontal activation. Imidafenacin seems safe in treating OAB patients due to neurologic diseases.
authors.affiliation: Department of Neurology and Internal Medicine, Sakura Medical Center, Toho University, 564-1 Shimoshizu, Sakura, 285-8741, Japan. sakakibara@sakura.med.toho-u.ac.jp
authors.forename: Ryuji
authors.initials: R
authors.lastname: Sakakibara
authors.forename: Fuyuki
authors.initials: F
authors.lastname: Tateno
authors.forename: Masashi
authors.initials: M
authors.lastname: Yano
authors.forename: Osamu
authors.initials: O
authors.lastname: Takahashi
authors.forename: Megumi
authors.initials: M
authors.lastname: Sugiyama
authors.forename: Takeshi
authors.initials: T
authors.lastname: Ogata
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Haruta
authors.forename: Masahiko
authors.initials: M
authors.lastname: Kishi
authors.forename: Yohei
authors.initials: Y
authors.lastname: Tsuyusaki
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Uchiyama
authors.forename: Tomonori
authors.initials: T
authors.lastname: Yamanishi
authors.forename: Chiharu
authors.initials: C
authors.lastname: Yamaguchi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003071:Cognition / Q000187:drug effects*; D003072:Cognition Disorders / Q000523:psychology; D004569:Electroencephalography; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D019265:Spectroscopy, Near-Infrared; D011795:Surveys and Questionnaires; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D014563:Urodynamics / Q000187:drug effects; D055815:Young Adult
chemical_list: D007093:Imidazoles; C120953:imidafenacin